Hong Kong stock movement: AB&B BIO-TECH-B rose 11.26%

Hong Kong Stock Movement Stocks with High Trading Volume in the Industry Yaojie Ankang-B plummeted 46.27%, with a trading volume of HKD 3.858 billion. According to recent important news: On September 16, Yaojie Ankang-B announced that the company's trading price and volume had recently experienced abnormal fluctuations. The board confirmed that it was unaware of any reasons for the abnormal changes in stock price and trading volume, and that there had been no significant changes in the company's business operations and financial condition. This announcement failed to quell market concerns, leading to a sharp decline in stock price. On September 16, the stock price of Yaojie Ankang-B surged 63% in the morning session but then fell back, indicating the market's high sensitivity to its stock price fluctuations. On September 15, Yaojie Ankang-B's semi-annual report showed that the company had no revenue in the first half of the year and incurred a loss of HKD 123 million. The market questioned the reasonableness of its high valuation, further exacerbating stock price volatility. The innovative drug sector performed actively overall, but caution is needed regarding short-term speculative risks. Tongyuan Kang Pharmaceutical-B surged 22.21%. Based on recent key news: On September 15, Tongyuan Kang Pharmaceutical-B announced that Zhang Senquan resigned as the company's independent non-executive director to devote more time to other business affairs. Following this news, investors expressed optimism about the company's governance structure adjustments, driving a significant increase in stock price. On September 15, Tongyuan Kang Pharmaceutical-B announced that after Zhang Senquan's resignation, he would no longer serve as the chairman of the board's audit committee, a member of the board's remuneration and assessment committee, and a member of the nomination committee. This move was interpreted by the market as a potential for more strategic adjustments in the company's future, further boosting the stock price. On September 15, Tongyuan Kang Pharmaceutical-B's announcement triggered a positive market reaction, with investors full of confidence in the company's future development prospects, leading to a significant rise in stock price. The industry trend is positive, with noticeable capital inflow. Stocks with High Market Capitalization in the Industry BeiGene fell 1.45%. Based on recent important news: On September 15, the National Healthcare Security Administration launched a new pricing mechanism for newly listed drugs, allowing innovative drugs to have greater pricing flexibility and a price protection period in the initial stage of market entry. This policy enhances the market competitiveness of companies like BeiGene and accelerates the commercialization process of products. On September 16, BeiGene announced a 45.78% increase in product revenue for the first half of 2025, with BeiYueZe® contributing over 70% of the revenue. The strong performance of this product in the global market boosted the company's overall performance. On September 12, market rumors suggested that the U.S. might impose restrictions on Chinese innovative drugs, putting pressure on the innovative drug sector in the short term. However, in the long term, China's biotechnology technology continues to break through, and the development prospects remain positive. The innovative drug sector is under short-term pressure but is viewed positively in the long term